Chemoprophylaxis Versus Immunoprophylaxis In Tuberculosis And Leprosy Infection

Bernadette Dian Novita

Abstract


Tuberculosis (TB) and leprosy are mycobacterial diseases that still represent significant public health challenges. Bacille Calmette–Guérin (BCG), the only available TB and Leprosy vaccine use as Immunoprophylaxis and has already given in infants. However, the evidence of TB and Leprosy infection in Indonesia remain high. In the last 10 years, chemoprophylaxis for both TB and leprosy were extensively done. However the effectiveness between immunoprophylaxis and chemoprophylaxis remains unclear.

Save to Mendeley


Full Text:

PDF

References


Chaptini C, Marshman G. Leprosy : a review on elimination , reducing the disease burden , and future research . Lepr Rev. 2015;86(4):307–15.

World Health Organization. Guidelines for surveilance of drug resistance in tuberculosis. 5th ed. 2015.

Pineda NIS, Pereira SM, Matos ED, Barreto ML. Chemoprophylaxis in the prevention of tuberculosis. J Bras Pneumol. 2004;30(4):485–94.

CDC. CDC core Curriciculum complete. In: What The Clinician Should Know. sixth edit. CDC Publisher; 2016. p. 21–47.

Chaptini C, Marshman G. Leprosy: a review on elimination, reducing the disease burden, and future research. Lepr Rev. 2015;86(4):307–15.

WHO. WHO Guidelines for the Diagnosis, Treatment and Prevention of Leprosy. In: 2nd ed. New Delhi; 2018. p. 87.

Kementerian Kesehatan Republik Indonesia. Data dan Informasi Profil Kesehatan Indonesia Tahun 2016. 2017. p. 100.

Smith WCS. Chemoprophylaxis in the prevention of leprosy. Bmj. 2008;336(7647):730–1.

Duthie M, Balagon MF. Combination chemoprophylaxis and immunoprophylaxis in reducing the incidence of leprosy. Risk Manag Healthc Policy. 2016;9:43–53.

Lockwood DNJ, Krishnamurthy P, Kumar B, Penna G. Single-dose rifampicin chemoprophylaxis protects those who need it least and is not a cost-effective intervention. 2018;10–3.

WHO. Report of the expert consultation on immunotherapeutic interventions for tuberculosis. In: 1. Geneva: WHO Publications; 2007.

Laurence B, Chapner B, Knollmann B. The Pharmacological Basis of Therapeutics-Goodman & Gillman-Ed. 12th ed. California: McGraw-Hill Companies; 2011.

Golan D, Tahjian A, Armstrong E, Armstrong A. Principles of Pharmacology : The Pathophysiologic Basis of Drug Therapy. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2012.

Katzung BG. Basic & Clinical Pharmacology. 14th ed. San Fransisco: McGraw-Hill Education; 2018.

Coppola M, van den Eeden S, Robbins N, Wilson L, Franken K, Adams L. Vaccines for Leprosy and Tuberculosis : Opportunities for Shared Research , Development , and Application. Front Immunol. 2018;9(February):1–12.

Smith C, Aerts A, Kita E, Virmond M. Time to define leprosy elimination as zero leprosy transmission? •. Lancet Infect Dis. 2019;3099(16):1–6.

Coppola M. Vaccines for Leprosy and Tuberculosis : Opportunities for Shared Research , Development , and Application. 2018;9(February):1–12.

Richardus JH, Oskam L. Protecting people against leprosy : Chemoprophylaxis and immunoprophylaxis. Clin Dermatol. 2015;33(1):19–25.

Metrics P. Time to define leprosy elimination as zero leprosy transmission? •. 2019;3099(16):1–6.

Mieras L, Anthony R, van Brakel W, Bratschi MW, van den Broek J, Cambau E, et al. Negligible risk of inducing resistance in Mycobacterium tuberculosis with single-dose rifampicin as post-exposure prophylaxis for leprosy. Infect Dis Poverty. 2016;5(1):1–5.

Biraro IA, Egesa M, Kimuda S, Smith SG, Toulza F, Levin J, et al. Effect of isoniazid preventive therapy on immune responses to mycobacterium tuberculosis : an open label randomised , controlled , exploratory study. BMC Infect Dis. 2015;1–12.




DOI: https://doi.org/10.33508/jwm.v6i1.2504